Free Trial

TScan Therapeutics Q1 2024 Earnings Report

TScan Therapeutics logo
$1.35 -0.10 (-6.90%)
As of 03/28/2025 04:00 PM Eastern

TScan Therapeutics EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.25
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

TScan Therapeutics Revenue Results

Actual Revenue
$0.57 million
Expected Revenue
$3.75 million
Beat/Miss
Missed by -$3.18 million
YoY Revenue Growth
N/A

TScan Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

TScan Therapeutics Earnings Headlines

TScan Therapeutics appoints Camiolo as SVP, Market Access
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
TScan Therapeutics assumed with an Overweight at Morgan Stanley
See More TScan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TScan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your email.

About TScan Therapeutics

TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

View TScan Therapeutics Profile

More Earnings Resources from MarketBeat